| Literature DB >> 33149205 |
Farid Kurniawan1,2,3, Dicky L Tahapary4,5, Karin de Ruiter3, Em Yunir1,2, Nienke R Biermasz6, Johannes W A Smit7,8, Taniawati Supali9, Erliyani Sartono3, Maria Yazdanbakhsh3, Pradana Soewondo1,2.
Abstract
In children, soil-transmitted helminth infections have been linked to poor nutritional status and growth retardation in association with lower levels of IGF-1. In adults, IGF-1 has an anabolic and metabolic function and is related to nutritional status. Here, we assessed the impact of helminth infection on free IGF-1 and its major binding protein, IGFBP-3, in adults. The levels of IGF-1 and IGFBP3 were measured in 1669 subjects aged ≥ 16 years, before and after receiving four rounds of albendazole 400 mg/day or matching placebo for three consecutive days. Helminth infection status was assessed by microscopy (Kato-Katz) and PCR. Serum free IGF-1 level was significantly lower in helminth-infected subjects [mean difference and 95% CI - 0.068 (- 0.103; - 0.033), P < 0.001 after adjustment for age, sex, body mass index, and fasting insulin level]. There was no difference in IGFBP-3 level between helminth infected versus non-infected subjects. In the whole study population, albendazole treatment significantly increased serum free IGF-1 level [estimate and 95% CI 0.031 (0.004; - 0.057), P = 0.024] whereas no effect was found on the IGFBP-3 level. Our study showed that helminth infection in adults is associated with lower free IGF-1 levels but not with IGFBP-3 and albendazole treatment significantly increases free IGF-1 levels in the study population.Clinical Trial Registration: https://www.isrctn.com/ISRCTN75636394 .Entities:
Mesh:
Substances:
Year: 2020 PMID: 33149205 PMCID: PMC7643058 DOI: 10.1038/s41598-020-75781-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics.
| Placebo | Albendazole | |
|---|---|---|
| Sex (n male, %) | 319 (38.2) | 308 (40.1) |
| Age (mean in years, SD) | ||
| Male | 44.45 (15.87) | 42.91 (15.73) |
| Female | 40.90 (15.21) | 42.29 (15.63) |
| BMI (kg/m2) (mean, SD) | ||
| Male | 21.81 (3.81) | 21.91 (3.58) |
| Female | 22.90 (4.33) | 22.73 (4.21) |
| Fasting insulina (mU/L) | 3.45 (3.22–3.73) | 3.52 (3.27–3.79) |
| Free IGF-1a (ng/mL) | 0.359 (0.337–0.382) | 0.369 (0.345–0.395) |
| Proportion of free IGF-1 below detection limit (%, n/N) | 35.9 (300/836) | 35.8 (275/768) |
| IGFBP-3a (ng/mL) | 424.75 (415.94–433.74) | 423.73 (414.17–433.51) |
| hsCRPa (mg/L) | 0.96 (0.89–1.04) | 0.97 (0.90–1.06) |
| Helminth infection by microscopy (%infected, n/N) | 44.2 (347/785) | 42.0 (300/714) |
| Number of helminth infection by microscopy (%infected, n/N) | ||
| 1 species | 27.8 (218/785) | 26.8 (191/714) |
| 2 species’ | 11.3 (89/785) | 11.6 (83/714) |
| 3 species’ | 5.1 (40/785) | 3.6 (26/714) |
| Helminth infection by PCR (%infected, n/N) | 54.6 (412/754) | 54.7 (375/686) |
| Number of helminth infection by PCR (%infected, n/N) | ||
| 1 species | 32.9 (248/754) | 35.4 (243/686) |
| 2 species’ | 16.7 (126/754) | 14.7 (101/686) |
| 3 species’ | 5.0 (38/754) | 4.5 (31/686) |
BMI body mass index, IGF-1 insulin-like growth factor-1, IGFBP-3 insulin-like growth factor binding protein-3.
aNon-normally distributed continuous variables, presented as geomean (95% CI).
Figure 1Serum free IGF-1 in males and females (a) and the association between IGF-1 and -age groups (b), -fasting insulin quartiles (c), and -BMI groups (d). Serum free IGF-1 level was presented as geometric mean and its 95% confidence interval. Serum free IGF-1 and fasting insulin levels are log transformed for analysis. BMI grouping was based on WHO classification for Asian population. (N for sex, age, fasting insulin quartiles grouping = 1604 subjects; N for BMI grouping = 1597 subjects).
Association between free IGF-1 or IGFBP-3 with STH infection status based on PCR (a) and microscopy (b).
| STH-infected | STH non-infected | Un-adjusted | Adjusted for age and sex | Adjusted for age, sex, and BMI | Adjusted for age, sex, BMI, and fasting insulin | ||
|---|---|---|---|---|---|---|---|
| (a) | Free IGF-1 (ng/mL) | 0.33 (0.31–0.35) | 0.41 (0.38–0.44) | − 0.090 (− 0.132; − 0.048), P < 0.001 | − 0.089 (− 0.125; − 0.053), P < 0.001 | − 0.078 (− 0.115; − 0.042), P < 0.001 | − 0.068 (− 0.103; − 0.033), P < 0.001 |
| IGFBP-3 (ng/mL) | 424.50 (415.38–433.81) | 423.94 (413.59–434.54) | 0.001 (− 0.014; 0.015), P = 0.937 | ||||
| (b) | Free IGF-1 (ng/mL) | 0.35 (0.33–0.38) | 0.37 (0.35–0.400) | − 0.027 (− 0.069; − 0.015), P = 0.202 | − 0.042 (− 0.078; − 0.006), P = 0.022 | − 0.033 (− 0.068; − 0.003), P = 0.074 | − 0.031 (− 0.066; − 0.003), P = 0.075 |
| IGFBP-3 (ng/mL) | 422.67 (412.79–432.79) | 424.66 (415.51–434.01) | − 0.002 (− 0.016; 0.012), P = 0.777 |
All variables are presented as geometric mean and its 95% confidence interval and were log transformed for analysis. Analysis for the difference between STH-infected and non-infected subjects was performed using linear regression and presented as estimated mean difference and its 95% confidence interval.
BMI body mass index, IGF-1 insulin-like growth factor-1, IGFBP-3 insulin-like growth factor binding protein-3, STH soil-transmitted helminth.
Figure 2Serum free IGF-1 level based on the number of helminth species detected by PCR (a) and microscopy (b). Serum free IGF-1 level was presented as geometric mean and its 95% confidence interval and were log-transformed for analysis. (N for PCR = 1440 subjects; N for microscopy = 1499 subjects).
Figure 3Effect of albendazole treatment on serum free IGF-1 and IGFBP-3 in the whole study population. The estimated treatment effect was obtained using linear mixed model and presented with its corresponding 95% confidence interval.